Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
FF/UMEC/VI · 1 trial · 1 indication
Change in VDP
| Arm | Type | Description |
|---|---|---|
| Participants with poorly controlled moderate to severe asthma | EXPERIMENTAL | Participants with poorly controlled moderate to severe asthma will be evaluated during and after a six week trial of triple therapy (ICS/LABA/LAMA) for changes in 129Xe MRI ventilation percent defect, pulmonary function measurements. |
| Name | Type | Description |
|---|---|---|
| FF/UMEC/VI | DRUG | The investigational drug is a single Ellipta inhaler containing 200 ug fluticasone furoate, 62.5 ug umedlidinium and 25 ug vilanterol. The drug is delivered in an Ellipta inhaler in a single dose once daily. |
Inclusion Criteria: * Participant understands study procedures and is willing to participate in the study as indicated by the participant's signature * Provision of written, informed consent prior to any study specific procedures * Males and females with a clinical diagnosis of eosinophilic asthma ...
FF/UMEC/VI is an investigational small molecule being developed for the treatment of asthma. It is a triple therapy combination being evaluated in a Phase 3 clinical trial. The drug is not yet approved and remains in clinical development.
FF/UMEC/VI is being developed by Grace Therapeutics, Inc., a biopharmaceutical company traded under the ticker GRCE. The company is conducting a Phase 3 clinical trial to evaluate the drug in patients with asthma.
FF/UMEC/VI is currently in Phase 3 clinical development for asthma. It is an investigational drug and has not been approved by regulatory authorities. The ongoing Phase 3 trial is active but not recruiting participants.
FF/UMEC/VI is being studied in a Phase 3 clinical trial with the identifier NCT04651777, titled 'Evaluation of Triple Therapy Using Magnetic Resonance Imaging in Asthma.' The trial is active but not recruiting, with an enrollment of 31 participants in Canada.
FF/UMEC/VI is a specific triple therapy combination being developed by Grace Therapeutics, Inc. It is not known to have alternative names. The drug is being studied for its effects in asthma using magnetic resonance imaging in a Phase 3 trial.